Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Xilio Therapeutics Inc.
Headquarters: Waltham, MA, United States of America
Website: http://www.xiliotx.com
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: René Russo, PharmD
Number Of Employees: 73
Enterprise Value: $-17,029,141
PE Ratio: -0.47
Exchange/Ticker 1: NASDAQ:XLO
Exchange/Ticker 2: N/A
Latest Market Cap: $41,429,300
BioCentury | Feb 19, 2025
Deals
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report
Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more
BioCentury | Dec 18, 2024
Management Tracks
David Apelian becomes CEO of Theolytics
Plus: John McDonough to resign as chairman from BioPorto, and updates from Caris, FibroGen, Akari and Xilio
BioCentury | Apr 2, 2024
Deals
Deals report: Abingworth and Blackstone bet on late-stage programs
Plus: Gilead acquires Xilio’s IL-12 program and Harmonic-Turbine to co-develop dark kinase therapy for cancer
BioCentury | Mar 18, 2022
Product Development
The IL-2 cancer pipeline remains deep, diverse
There’s still hope for ‘not-alpha’ IL-2 therapies after Nektar’s Ph III failure, with a pipeline full of diverse modalities and MOAs
BioCentury | Nov 9, 2021
Management Tracks
Maraganore joins board at Beam
Plus: new CBO, board member at Caribou, Nordic, GT Biopharma and more
BioCentury | Oct 23, 2021
Product Development
Oct. 22 Quick Takes: FDA approves Genentech’s ocular implant for wet AMD
$118M IPO values Xilio at $427M, plus Genentech, Merck, Sanofi and more
BioCentury | Oct 13, 2021
Management Tracks
Harler joins IGM as president of autoimmunity and inflammation business
Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more
BioCentury | Oct 5, 2021
Product Development
Oct. 4 Quick Takes: 80% efficacy for J&J RSV vaccine
Plus: Xenon, Atara-Pierre Fabre, Takeda-Selecta, LianBio, Xilio, Enanta
BioCentury | Sep 17, 2021
Product Development
Sept. 16 Quick Takes: Moderna data support COVID booster shots as Spikevax gains first full approval
Plus: Theseus readies for IPO, Oxitope launches, Allay, MiMedx, Roche-Temedica
BioCentury | May 5, 2021
Management Tracks
Clackson joins Theseus as CEO, plus Calliditas, Cerevel, VistaGen, Escient and Shoreline
Theseus Pharmaceuticals Inc. hired Tim Clackson as president and CEO to succeed Iain Dukes, the co-founder and OrbiMed venture partner who has held the CEO role on an interim basis. Dukes will
Items per page:
1 - 10 of 23